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Tumor suppressionHistone deacetylase (HDAC) inhibitors (HDIs) have therapeutic potentials for treating cancer and other diseases.
Modulation of gene expression by HDIs is a major mechanism underlying their therapeutic effects. A novel class
of HDIswith a previously undescribed benzoylhydrazide scaffold has been discovered through a high throughput
screening campaign. Usingmicroarray proﬁling of gene expression, we have previously demonstrated that treat-
ment of breast cancer cellswith a lead benzoylhydrazideHDI UF010 results in cell cycle arrest and apoptosis, like-
ly through activation of tumor suppression pathways with concurrent inhibition of oncogenic pathways. In this
brief report, we showmethodological and analytical details and discuss additional pathways such as immune sig-
naling that are affected by UF010. Raw and processed data from the microarray were deposited in NCBI's Gene
Expression Omnibus (GEO) database under the accession number: GSE56823.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell line/tissue Human/MDA-MB-231/Breast, derived from
metastatic site (pleural effusion)Sex Female (51 years adult)
Sequencer or array type Affymetrix GeneChip Human
Transcriptome Array 2.0
Data format CEL ﬁles
Experimental factors Cultured MDA-MB-231 cells exposed to
DMSO control
(n = 3) or benzoylhydrazide HDAC
inhibitor UF010 (n = 3)Experimental features Assess effects of UF010 treatment on
global gene expression in cancer cellsConsent N/A
Sample source location ATCC (www.atcc.org)1. Direct link to deposited genomic data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56823.and Cell Biology, University of
e, FL 32610, United Sates.
. This is an open access article under2. Experimental design, materials and methods
2.1. Experimental design
A novel class of small molecule HDIs with a benzoylhydrazide
scaffold has been discovered recently [1]. They are speciﬁc to class I
HDACs 1–3 and appear to exhibit fast-on/slow-off target-binding
mechanism. Therefore, the new inhibitors are distinct chemically and
mechanistically from known HDIs such as hydroxamic acids and
benzamides. As histone deacetylation plays a major role in transcrip-
tional regulation [2–4], we have assessed impact of the new HDIs on
global gene expression. We used the triple-negative breast cancer cell
line MDA-MB-231 and the benzoylhydrazide analog UF010 to interro-
gate effects of the new HDIs on gene expression. The experimental de-
sign is summarized in Fig. 1.2.1.1. Cell culture and drug treatment
MDA-MB-231 cells were obtained from ATCC and cultured with
Dulbecco's Modiﬁed Eagle Medium (DMEM) supplemented with 10%
bovine calf serum, penicillin to 10 units/ml, and streptomycin to 10 µ/ml.
Cells (500,000 cells per well) were seeded in a 6-well plate. At 24 h
after seeding, dimethyl sulfoxide (DMSO) or UF010 was added. The
ﬁnal concentration for UF010 was 1 μM.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A schematic diagram of gene expression proﬁling of MDA-MB-231 cells treated
with a new HDI (UF010). MDA-MB-231 cells were cultured and then exposed to DMSO
(control) or to UF010. Total RNAs were isolated from the treated cells and then processed
for hybridization to microarray chips (Affymetrix GeneChip Human Transcriptome Array
2.0). The chipswere scanned and data captured. Datawere processed (background adjust-
ment, summarization and normalization). The selected statistically signiﬁcant genes in the
experimental groupswere analyzed for functional enrichments in certain pathways using
Ingenuity Pathway Analysis (IPA) software.
258 I. Mahmud, D. Liao / Genomics Data 5 (2015) 257–2592.1.2. RNA isolation and processing
Total RNAs from the treated cells were isolated using the RNeasy kit
(Qiagen) and submitted to the Gene Expression Core of the University of
Florida Interdisciplinary Center for Biotechnology Research. A NanoDrop
Spectrophotometer (NanoDrop Technologies, Inc.) was used to determine
RNA concentration and sample qualitywas assessed using anAgilent 2100
Bioanalyzer (Agilent Technologies, Inc.).2.1.3. Microarray probe preparation, hybridization and data acquisition
The Ambion®WT Expression Kit, the GeneChipWT Terminal Label-
ing and Controls Kit (Affymetrix) were used for all microarray probe
preparation following manufacturer's protocols. We used 200 ng ofD
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Fig. 2. Quality control assessments for the dataset. A, a plot of the log-intensity distribution in
intensity levels between the arrays of the dataset. Either end of the box represents the upper a
comparison of the six samples in the dataset. D, DMSO; T, UF010 treatment.total RNA as template for cDNA synthesis. The resulting cDNA was
used as template for in vitro transcription (IVT) to generate antisense
RNAs, which were then used to produce sense DNA. The sense strand
DNA was fragmented, biotinylated, and hybridized with rotation at
45 °C for 16 h to microarray chips (GeneChip® Human Transcriptome
Array 2.0, Affymetrix). The arrays were washed and stained with
streptavidin-phycoerythrin (SAPE) with an Affymetrix Fluidics Station
450, and scanned using a GeneChip® 7G scanner (Affymetrix).
2.1.4. Microarray data quality control and analysis
The Affymetrix® Expression Console™ Software (Version 1.3) was
used to generate.txt ﬁles for each RNA hybridization. All subsequent
data analyses were performed in R 3.0.0 (http://www.R-project.org/).
The Limma package [5] was used for background adjustment, summari-
zation and quantile normalization. Normalization was made using the
Robust Multichip Average (RMA) pre-normalization algorithm [6].
Data quality was assessed using various quality control measures. Spe-
ciﬁcally, density plots were generated to assess log-intensity distribu-
tions across a chip. The ideal distributions of the chips show no
signiﬁcant variation (Fig. 2A). An intensity boxplot (Fig. 2B) was used
to compare the probe intensity levels between the arrays of the dataset.
After normalization, the median lines are not signiﬁcantly different
from each other (Fig. 2B). A heatmap of the six sampleswas constructed
to compare the UF010-treated cells with control (Fig. 2C). For each rep-
licate array, each probe-set signal value from UF010-treated samples
was compared to the probe-set signal value of DMSO-treated control
samples to give gene expression ratios. Differentially expressed genes
were identiﬁed using the Limma package with a Benjamini and
Hochberg false discovery rate multiple testing correction. The statisti-
cally signiﬁcant or differentially expressed genes were calculated
using volcano plot analysis with a fold change (FC) threshold of N1.5
and a p value of b0.05.
2.1.5. Ingenuity pathway analysis
The Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems
Inc., Redwood City, CA) was used for functional enrichment analysis of
the selected statistically signiﬁcant genes in each of these experimental
groups. The association between the genes in the dataset and a func-
tional pathway were made using Fisher's exact test. Functional groups
(or pathways) with a P value less than 0.05 and at least one focused
molecule in a pathway were considered to be statistically signiﬁcant.
3. Results
Analyses of themicroarray dataset reveal that the benzoylhydrazide
HDI UF010 induces gene activation and repression, consistentwithﬁnd-
ings by others that HDIs can up and downregulate gene expression2 T3
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by UF010with downregulation of genes that promote and upregulation
of those that inhibit cell-cycle progression [1]. Induction of cell cycle ar-
rest and cell death is a common mechanism of action by HDIs irrespec-
tive of cancer or inhibitor types [1,8,9]. Interestingly, UF010 treatment
activates major histocompatibility complex (MHC) genes and other
genes involved in immune response. Pathway analysis suggests that
UF010 speciﬁcally induces B-cell receptor, IL-6 and IL-4 signaling.
Activation of MHC and immune-related genes by other HDIs in prostate
cancer cell lines has been reported [8].
4. Discussion
The class I HDACs 1–3 play important roles in gene regulation and
are overexpressed in cancer [13–17]. HDACs 1 and 2 are closely related
and assembled together in deacetylase complexes such as Sin3, NuRD
and CoREST [18,19]. HDAC3 is found in the NCOR complex and depends
on the deacetylase activation domain (DAD) of NCOR1 or NCOR2 and D-
myo-inositol-(1,4,5,6)-tetrakisphosphate for catalyzing deacetylation
reaction [20]. Thus, these HDACs may regulate gene expression in a dif-
ferent way and HDIs speciﬁc to an individual HDAC isoform may exert
distinct impact on gene expression. Different chemical types of small
molecule HDIs have been discovered. Hydroxamic acids are potent
HDIs and exhibit strong Zn2+-binding property, which limits their iso-
form selectivity. Nonetheless, isoform selectivity can be achieved
through modifying the “cap” moiety that interacts with the residues in
the rim outside the substrate tunnel [21]. Benzamide analogs occupy
the catalytic center of HDACs and coordinate Zn2+ using the amine
and carbonyl groups in a bidentatemanner [22]. Benzamide derivatives
with a ﬁve or six-membered aromatic ring “internal cavity” motif
exhibit strong selectivity for HDACs 1 and 2 vs. HDAC3 [22], while
HDAC3 selectivity is achieved by modifying the “cap” groups [21]. The
benzoylhydrazide HDIs appear to use a linear aliphatic chain to bind
the internal hydrophobic cavity of HDACs and they display notable
selectivity for HDAC3, while inhibiting HDACs 1 and 2 with similar
potency [1]. UF010 shows a fast-on/slow-off target binding mechanism.
Whether the unique chemistry and pharmacology of the
benzoylhydrazide HDIs can result in distinct modulation of gene expres-
sion and therapeutic effects remains to be determined.
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